AVH AVITA Medical CDI

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time.

A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit .

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.



Investor & Media Contact:
Jessica Ekeberg
Phone  
 
 
EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AVITA Medical CDI

 PRESS RELEASE

CMS New Technology Add-On Payment Expands Access to RECELL® for Patien...

CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today announced that beginning October 1, 2025, hospitals across the U.S. will be eligible f...

 PRESS RELEASE

AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercializat...

AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialize RECELL GO in Europe and in other markets that recognize the CE Mark. “CE Mark for RECELL® GO is an important milestone for AVITA Medical and for patients,” said Jim Corbett, Chief Ex...

 PRESS RELEASE

Real-World Data Shows Significant Reduction in Hospital Stay Using AVI...

Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin graftingMore than $42,000 per patient cost savings, together with improved patient throughput, support operational and economic value Presented at the 2025 European Burn Association Congress in Berlin, Germany VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) --  AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therap...

 PRESS RELEASE

AVITA Medical Announces September Investor Conference Participation

AVITA Medical Announces September Investor Conference Participation VALENCIA, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that senior management will participate in three investor conferences this September. Upcoming investor conference participation includes: Cantor Global Healthcare Conference – September 4, 2025 | 10:55 a.m. EST fireside chat with CFO David O’Toole | New YorkMorgan Stanley 23rd Annual Global Healthcare Conference – September ...

 PRESS RELEASE

AVITA Medical Successfully Completes Australian Equity Raise

AVITA Medical Successfully Completes Australian Equity Raise Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch